title: Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
authors.forename: Maejima
authors.initials: M
authors.lastname: Hideki
authors.forename: Takano
authors.initials: T
authors.lastname: Tetsurou
authors.forename: Funatsu
authors.initials: F
authors.lastname: Sakae
authors.forename: Katsuoka
authors.initials: K
authors.lastname: Kensei
authors.forename: Oobe
authors.initials: O
authors.lastname: Makoto
authors.forename: Kamata
authors.initials: K
authors.lastname: Toshinobu
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D016983:Enterococcus; D017809:Fatal Outcome; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D009154:Mutation; D018410:Pneumonia, Bacterial / Q000382:microbiology; D011239:Prednisolone / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy / Q000235:genetics*
chemical_list: D000893:Anti-Inflammatory Agents; D011239:Prednisolone; D053614:Janus Kinase 2